The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") have opportunity to lead the securities fraud class ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...

We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...

Claro Advisors LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 15.7% in the 4th ...

For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Regeneron Pharmaceuticals, Inc ...

Tuesday closed up +0.11%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.52%, and the Nasdaq 100 Index ($IUXX) ...

Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regeneron ...